Table 2.
Retrospective study. Baseline demographics and clinical characteristics of JAK2V617F patients from the outpatient clinic at the time of first JAK2V617F measurement
| Characteristics | ET | PV | Post‐PV MF | Total |
|---|---|---|---|---|
| (n = 1) | (n = 4) | (n = 1) | (n = 6) | |
| Age (y) | 68 | 66 (59‐70) | 75 | 68 (59‐75) |
| Gender, male | 0 (0) | 4 (80) | 1 (100) | 5 (83) |
| History of major thrombohemorrhagic event | 0 (0) | 3 (75) | 0 (0) | 3 (50) |
| Prior cytoreductive therapy | 1 (100) | 2 (50) | 1 (100) | 4 (67) |
| Hydroxyurea | 1 (100) | 0 (0) | 1 (100) | 2 (33) |
| r‐IFNα‐2a | 1 (100) | 1 (100) | 1 (100) | 3 (50) |
| r‐IFNα‐2b | 0 (0) | 1 (100) | 0 (0) | 1 (17) |
| Time off cytoreductive therapy before first JAK2V617F measurement (months) | 0.5 | 1.2 (0.6‐1.8) | 5.3 | 1.2 (0.5‐5.3) |
| JAK2V617F allele (%) | 6 | 6 (0.7‐27) | 93 | 8.5 (0.7‐96) |